Both the Vanguard Small-Cap Value ETF (NYSEMKT:VBR) and the State Street SPDR S&P 600 Small Cap Value ETF (NYSEMKT:SLYV)target the "value" slice of the small-cap market, holding companies that trade at low price multiples relative to fundamental metrics. However, they trac
Prediction: SpaceX, Anthropic, and OpenAI Will Push the S&P 500 Dividend Yield to an All-Time Low. Here's What Income Investors Can Do About It SpaceX is planning its initial public offering (IPO) for June 12, raising $75 billion at a valuation of $1.77 trillion. An
The past couple of years have been a rollercoaster ride for Airbnb (NASDAQ:ABNB) stock investors. The company is widely viewed as a pioneer in the "sharing economy," carving out a successful niche in home rentals and the travel industry Under the leadership of CEO B
OpenAI Just Filed for an IPO After Anthropic Beat It to the Punch. Here's What That Means for the AI Investing Race One week after artificial intelligence company Anthropic filed for a confidential IPO, its biggest competitor tossed its own hat into the ring. OpenAI
Snowflake (SNOW) wants to convince Wall Street its next act is larger than cloud data storage. Bank of America seems to be buying the pitch BofA Securities came out more bullish on Snowflake after the company’s investor day, reiterating a Buy rating and $300 price t
Americans with a retirement plan are more confident about their future Having a written retirement plan significantly increases confidence in one's financial future. 81% of retirees with a plan believe their money will last a lifetime, compared to 45% without one. T
Libre Duo systems will allow real-time monitoring of glucose and ketones without blood or urine tests, launching in Europe later this year. Abbott Laboratories secured CE Mark approval for Libre Duo and Libre Duo 10 Day, the first continuous glucose-ketone sensing technolo
Downgrade follows Wolfe Research’s coverage initiation, citing comparable growth and cheaper Thermo Fisher on P/E multiples. Wolfe Research downgraded Danaher Corporation (DHR) to Peer Perform from Outperform, removing its price target after initiating coverage. The firm n
Roivant Sciences reports $4.3 billion in cash reserves and higher R&D spending for fiscal Q4 ended March 31, 2026. Guggenheim increased its price target for Roivant Sciences Ltd. (NASDAQ:ROIV) to $36 from $30, maintaining a Buy rating after the company’s fiscal Q4 earnings
HCA Healthcare, Inc. (NYSE:HCA) is one of the best healthcare stocks to buy with highest upside potential. HCA Healthcare, Inc. (NYSE:HCA) and The College of Health Care Professions announced on May 27 an agreement for HCA Healthcare to acquire ownership of CHCP CHC
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.